Drug Information

Drug General Information
Drug ID
D0C8PE
Former ID
DNCL003124
Drug Name
JNJ-37822681
Drug Type
Small molecular drug
Indication Schizophrenia [ICD9: 295; ICD10:F20] Phase 2 [522393]
Company
Johnson & Johnson Pharmaceutical Research & Development
Formula
C17H17F5N4
PubChem Compound ID
16058752
Target and Pathway
Target(s) D(2) dopamine receptor Target Info Agonist [532392]
KEGG Pathway Rap1 signaling pathway
cAMP signaling pathway
Neuroactive ligand-receptor interaction
Gap junction
Dopaminergic synapse
Parkinson's disease
Cocaine addiction
Alcoholism
PANTHER Pathway Heterotrimeric G-protein signaling pathway-Gi alpha and Gs alpha mediated pathway
Heterotrimeric G-protein signaling pathway-Gq alpha and Go alpha mediated pathway
Dopamine receptor mediated signaling pathway
Nicotine pharmacodynamics pathway
Reactome Dopamine receptors
G alpha (i) signalling events
WikiPathways Hypothetical Network for Drug Addiction
Monoamine GPCRs
GPCRs, Class A Rhodopsin-like
Genes and (Common) Pathways Underlying Drug Addiction
GPCR ligand binding
GPCR downstream signaling
Nicotine Activity on Dopaminergic Neurons
References
Ref 522393ClinicalTrials.gov (NCT00728195) An Efficacy and Safety Study of 3 Fixed Doses of JNJ-37822681 in Participants With Schizophrenia. U.S. National Institutes of Health.
Ref 532392Population pharmacokinetics of JNJ-37822681, a selective fast-dissociating dopamine D??receptor antagonist, in healthy subjects and subjects with schizophrenia and dose selection based on simulated D??receptor occupancy. Clin Pharmacokinet. 2013 Nov;52(11):1005-15.

If you find any error in data or bug in web service, please kindly report it to Dr. Tang and Dr. Mou.